Last reviewed · How we verify
Cyclosporine emulsion
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Dry eye disease, Organ transplant rejection prevention, Autoimmune conditions (e.g., rheumatoid arthritis, psoriasis).
At a glance
| Generic name | Cyclosporine emulsion |
|---|---|
| Sponsor | Baylor College of Medicine |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (protein phosphatase 2B) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Cyclosporine binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response. The emulsion formulation improves bioavailability and absorption compared to conventional cyclosporine preparations.
Approved indications
- Dry eye disease
- Organ transplant rejection prevention
- Autoimmune conditions (e.g., rheumatoid arthritis, psoriasis)
Common side effects
- Nephrotoxicity
- Hypertension
- Tremor
- Gingival hyperplasia
- Hirsutism
- Infection
Key clinical trials
- Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (PHASE4)
- Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) (NA)
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (PHASE3)
- A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis (PHASE2)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device (PHASE1, PHASE2)
- 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin) (PHASE3)
- Effect of Cequa™ in Subjects With Dry Eye Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporine emulsion CI brief — competitive landscape report
- Cyclosporine emulsion updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI